Can Covaxin Neutralize the Delta variant of Corona, know what has been revealed in a study by America's National Institutes of Health?

Shrestha Seal

Writer | Posted on 1-Jul-2021

Bharat Biotech has collaborated with the Indian council of medical research to develop Covaxin of India. The National Institute of Health has declared that this Covaxin has succeeded in neutralizing the effect of both Delta and Alpha variants of coronavirus.

According to the study of blood serum of the people who have received Covaxin, NIH suggested that this vaccine helps in the production of antibodies to fight against the Delta and Alpha variants of SARS-CoV-2.

Image Source: Google

According to the top American health research institute, adjuvants developed in collaboration with India are the reason behind the success of highly effective Covaxin. Adjuvants are substances that boost your immune system and also enhance the working power of any vaccine. Nearly 25 million people all over the world have undergone the Covaxin vaccination process till now.

Alhydroxiquim II is the adjuvant present in Covaxin. Kansas, ViroVax LLC of Biotech company Lawrence has tested this adjuvant in coordination with NIAID Adjuvant Development Program. This adjuvant is responsible for activating receptors to boost the virus-fighting immune system i.e. TLR 7 and TLR 8. Besides, NIH has stated that the side effects of Alhydroxiquim II are mild enough.

Image Source: Google

Bharat Biotech obtained a license to use Alhydroxiquim II. The license was renewed when Covid-19 Pandemic took place to use this adjuvant in the development of Covaxin. They have also received authorization for emergency use in several countries along with India.

Both Phase 2 and phase 3 trials have been completed with Covaxin. But NIH announced that the report of the phase 3 trial will be made public in the latter part of this year. According to those reports, Covaxin is safe and secured for everyone.